Pharmaceuticals

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

GRIN Therapeutics expands its pivotal Phase 3 study for radiprodil to Europe, fueling hope for a first-ever targeted therapy for a rare neurological disorder.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

The electric vehicle innovator plans a public debut through a SPAC deal, aiming to revolutionize the global cold-chain with its smart refrigerated trucks.

A new company emerges from Purdue Pharma's bankruptcy, owned by a non-profit and tasked with fighting the very opioid crisis its predecessor fueled.

Consumers and insurers who bought QVAR inhalers may get cash from a $35M settlement over claims Teva illegally blocked cheaper generic alternatives.

With $2.5M in seed funding, Hamilton's Stoked Bio is using a novel AI platform to tackle the world's toughest diseases, from superbugs to brain cancer.

Following a year of record profits, Cipher Pharmaceuticals is renewing its share buyback program, signaling a strong belief that its stock is undervalued.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

With double-digit growth and key US acquisitions, ESTEVE is rapidly expanding. But it's the firm's B Corp status that may redefine success in pharma.

A triple awards ceremony honors brands moving beyond profit, celebrating ethical governance, Halal leadership, and sustainable growth as the new currency of excellence.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

New Phase III data shows a dual-action drug delivers significant weight loss while targeting liver health, positioning it as a major new player in the market.

The clinical trial leader renewed a key global certification, signaling a new era of quality and trust that could accelerate breakthroughs in Alzheimer's.

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

A new alliance between AssureCare and Pillr Health will use AI and analytics to help hospitals manage soaring specialty drug costs and improve patient care.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

As RNA therapies boom, a new enzymatic platform promises to solve critical manufacturing bottlenecks, making next-gen drugs more scalable and sustainable.